$10 Billion Deal, page-5694

Evansblue

sounds like there is a mix of stories hear being combined into one.

There are several CV studies happening in Australia for vaccines and for antivirals. BIT is working on an antiviral, but there is no guarantee that it is 225, their main drug for HIV. They have other compounds that are viroporin inhibitors, just as 225 is in the case of HIV (it acts on the Vpu protein). They have other compounds that they've used against SARS1 and other RNA viruses that have ion channel inhibitor efficacy. In the case of SARS1, the ion channel proteins are N15 and V25. SARS-Cov-2, the coronavirus that causes COVID-19, also contains these molecules.

China is testing Remdesivir, a failed Ebola antiviral made by Gilead, which did show efficacy against MERS in monkeys. MERS is more distant to SARS-CoV2 than SAR1 is. The drug is undergoing a quick phase 3 type study in both Chine and the US after it was used on compassionate grounds on the first infected patient in the US. He recovered, but we still don't know if it was because of Remdesivir. Let's hope it was.

As you can see, when people speak loosely of HIV antivirals being used presently to treat COVID patients, as well as new ones being tested, and then we have BIT with a highly regarded new HIV antiviral, possibly also being tested on CV (or not), as well as other compounds possibly able to treat the virus, there is plenty of room for mix-up.









China